Ning M, Guo Y, Pan H, Chen X, Gu Z (2005) Preparation, in vitro and in vivo evaluation of

liposomal/niosomal gel delivery systems for clotrimazole. Drug Dev Ind Pharm 31:375–383.

https://doi.org/10.1081/ddc-200054315

Obeidat WM, Schwabe K, Müller RH, Keck CM (2010) Preservation of nanostructured lipid

carriers (NLC). Eur J Pharm Biopharm 76:56–67. https://doi.org/10.1016/j.ejpb.2010.05.001

Otberg N, Richter H, Schaefer H, Blume-Peytavi U, Sterry W, Lademann J (2004) Variations of

hair follicle size and distribution in different body sites. J Invest Dermatol 122:14–19. https://

doi.org/10.1046/j.0022-202X.2003.22110.x

Phatak AA, Chaudhari PD (2013) Development and evaluation of nanostructured lipid carrier

(NLC) based topical delivery of an anti-inflammatory drug. J Pharm Res 7:677–685. https://

doi.org/10.1016/j.jopr.2013.08.020

Puglia C, Bonina F (2012) Lipid nanoparticles as novel delivery systems for cosmetics and dermal

pharmaceuticals. Expert Opin Drug Deliv 9:429–441. https://doi.org/10.1517/17425247.2012.

666967

Puglia C, Damiani E, Offerta A, Rizza L, Tirendi GG, Tarico MS, Curreri S, Bonina F, Perrotta RE

(2014) Evaluation of nanostructured lipid carriers (NLC) and nanoemulsions as carriers for

UV-filters: characterization, in vitro penetration and photostability studies. Eur J Pharm Sci 51:

211–217. https://doi.org/10.1016/j.ejps.2013.09.023

Raza K, Singh B, Singla S, Wadhwa S, Garg B, Chhibber S, Katare OP (2013) Nanocolloidal

carriers

of

isotretinoin:

antimicrobial

activity

against

propionibacterium

acnes

and

dermatokinetic modeling. Mol Pharm 10:1958–1963. https://doi.org/10.1021/mp300722f

Rossi ABR, Vergnanini AL (2000) Cellulite: a review. J Eur Acad Dermatology Venereol 14:251–

262. https://doi.org/10.1046/j.1468-3083.2000.00016.x

Scheuplein RJ (1967) Mechanism of percutaneous absorption. II. Transient diffusion and the

relative importance of various routes of skin penetration. J Invest Dermatol 48:79–88. https://

doi.org/10.1038/jid.1967.11

Shah VP (2001) Progress in methodologies for evaluating bioequivalence of topical formulations.

Am J Clin Dermatol 2:275–280. https://doi.org/10.2165/00128071-200102050-00001

Sharma G, Dhankar G, Thakur K, Raza K, Katare OP (2016a) Benzyl benzoate-loaded

microemulsion for topical applications: enhanced dermatokinetic profile and better delivery

promises. AAPS PharmSciTech 17:1221–1231. https://doi.org/10.1208/s12249-015-0464-0

Sharma G, Kaur M, Raza K, Thakur K, Katare OP (2016b) Aceclofenac-β-cyclodextrin-vesicles: a

dual carrier approach for skin with enhanced stability, efficacy and dermatokinetic profile. RSC

Adv 25:20713–20727. https://doi.org/10.1039/C5RA24516H

Sharma G, Saini MK, Thakur K, Kapil N, Garg NK, Raza K, Goni VG, Pareek A, Katare OP (2017)

Aceclofenac cocrystal nanoliposomes for rheumatoid arthritis with better dermatokinetic

attributes: a preclinical study. Nanomedicine 12:615–638. https://doi.org/10.2217/nnm-

2016-0405

Shen LN, Zhang YT, Wang Q, Xu L, Feng NP (2014) Enhanced in vitro and in vivo skin deposition

of apigenin delivered using ethosomes. Int J Pharm 460:280–288. https://doi.org/10.1016/j.

ijpharm.2013.11.017

Swain S, Beg S, Babu SM (2015) Liposheres as a novel carrier for lipid based drug delivery: current

and future directions. Recent Pat Drug Deliv Formul 10:59–71. https://doi.org/10.2174/

1872211309666151001143335

Thakur CK, Thotakura N, Kumar R, Kumar P, Singh B, Chitkara D, Raza K (2016) Chitosan-

modified PLGA polymeric nanocarriers with better delivery potential for tamoxifen. Int J Biol

Macromol 93:381–389. https://doi.org/10.1016/j.ijbiomac.2016.08.080

Thakur K, Mahajan A, Sharma G, Singh B, Raza K, Chhibber S, Katare OP (2020) Implementation

of quality by design (QbD) approach in development of silver sulphadiazine loaded egg oil

organogel: an improved dermatokinetic profile and therapeutic efficacy in burn wounds. Int J

Pharm 576:118977. https://doi.org/10.1016/j.ijpharm.2019.118977

Thiboutot D, Del Rosso JQ (2013) Acne vulgaris and the epidermal barrier: is acne vulgaris

associated with inherent epidermal abnormalities that cause impairment of barrier functions?

14

Lipodermaceuticals: Technological Transformations

229